Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study

Table 1 Patient characteristics of the entire study cohort before and after propensity-score matching

Variables	Before matching			After matching
Variables	Argatroban n = 39	UFH n = 465	SMD	Argatroban n = 39	UFH n = 78	SMD	p value
Age, years	55 (46; 61)	53 (40; 62)	0.197	55 (46; 61)	56 (48; 63)	0.096	0.538
Female patients	10 (26)	138 (30)	0.194	10 (26)	27 (35)	0.151	0.325
BMI, kg/m²	27.7 (24.9; 34.0)	27.8 (24.5; 33.0)	0.006	27.7 (24.9; 34.0)	29.2 (24.9; 33.2)	0.095	0.675
SOFA	12.0 (10.0; 15.0)	12.0 (9.0; 15.0)	0.124	12.0 (10.0; 15.0)	12.0 (9.0; 14.3)	0.153	0.354
ARDS subgroup			0.549			0.284	0.816
I: pulmonary	31 (79)	281 (60)	–	31 (79)	60 (77)	–
II: non-pulmonary	5 (13)	95 (20)	–	5 (13)	9 (11)	–
III: post-trauma	0 (0)	43 (9)	–	0 (0)	2 (3)	–
IV: mis-cellaneous	3 (8)	46 (10)	–	3 (8)	7 (9)	–
Days of ventilation before ECMO	1 (0; 2)	1 (1;4)	0.212	1 (0; 2)	1 (0; 2)	0.146	0.774
Resuscitation before ECMO	8 (21)	74 (16)	0.119	8 (21)	15 (19)	0.032	0.869
Days on ECMO support	11 (8; 16)	8 (6; 14)	0.349	11 (8; 16)	10 (6; 16)	0.086	0.303

Data are expressed as n (%), median (25. percentile; 75. percentile); miscellaneous includes drowning, pulmonary embolism, cystic fibrosis, and bridge to transplant; ARDS: acute respiratory distress syndrome; UFH: unfractionated heparin; SMD: standardized mean difference

ISSN: 1364-8535